Biocidin REMOVE

Phase 2

JJohns Hopkins University

Biocidin REMOVE is one of 2 therapeutic programs targeting Irritable Bowel Syndrome (IBS). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Irritable Bowel Syndrome (IBS)Not yet recruiting

Irritable Bowel Syndrome (IBS)Phase 2

Not yet recruiting

Competition

Competitive Landscape

1 competitor in Irritable Bowel Syndrome (IBS)

#DrugCompanyPhaseTrials

Biocidin REMOVE

JJohns Hopkins University

Phase 2

1 2

Routine Treatment

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Not yet recruiting

Irritable Bowel Syndrome (IBS)

NCT07768267

Clinical

Trials by Indication[1]

Irritable Bowel Syndrome (IBS)1 trial

A Pilot Study of the Role of an Antimicrobial Herbal Formulation (Biocidin REMOVE) for the Management of Small Intestinal Bacterial Overgrowth (SIBO) in Patients With Irritable Bowel Syndrome (IBS)

Not yet recruiting·JJohns Hopkins University·Phase 2·NCT07768267·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Biocidin REMOVE. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Biocidin REMOVE. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Johns Hopkins University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: JJohns Hopkins University

Biocidin REMOVE

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Irritable Bowel Syndrome (IBS)1 trial

References

Drug Info

Quick Facts

Related News